NIH funding squeeze intensifies
NIH got a modest appropriations increase for FY2026, but heightened competition makes grants rare and mobility of top scientists to better‑resourced institutions has risen—illustrated by an NIH‑funded researcher moving from UCSF to Shanghai. The environment pressures labs to diversify funding, strengthen mentorship, and protect research continuity. (cen.acs.org) (scmp.com)
Congress set NIH’s FY2026 discretionary funding at $48.7 billion, a $415 million (≈0.9%) increase over FY2025 enacted levels. (genomeweb.com) The FY2026 minibus preserved existing indirect‑cost (F&A) policies and included language restricting how much forward‑funding NIH can use and requiring NIH to notify Congress before terminating grants. (acr.org) NIH data show the number of investigators awarded R01‑equivalent grants fell from 7,720 in FY2024 to 5,885 in FY2025, a decline the agency reported in a Feb. 10, 2026 Office of Extramural Research post. (science.org) Agency and sector analyses estimate NIH’s increased use of upfront multiyear (forward) funding will reduce the pool of competing new awards by roughly 970 in FY2026 compared with a 2024‑style funding mix. (cen.acs.org) Prominent NIH‑funded biophysicist Xiaokun (Xiaokun) Shu left a recent Herfindahl Endowed Chair appointment at UCSF to become a distinguished professor and founding director of Fudan University’s iCOBRA institute in March 2026. (scmp.com) NIH’s NOT‑OD‑26‑059 notice requires Institutes and Centers to post FY2026 fiscal policies on multiyear awards and confirms administrative adjustments such as modest NRSA stipend increases for predocs and postdocs. (grants.nih.gov) C&EN, Science and policy groups link the FY2025 funding contraction and FY2026 fiscal rules to hiring slowdowns, renewed emphasis on non‑NIH revenue streams (foundations, industry partnerships), and rising international mobility among well‑funded investigators. (cen.acs.org)
